Search for a trial

Rituximab in Primary Central Nervous system Lymphoma.
A randomized HOVON / ALLG intergroup study

Primary objectiveTo assess the effect of the addition of rituximab in a standard chemotherapy regime on EFS in newly diagnosed PCNSL.Secondary objectiveTo evaluate the effect of the addition of rituximab to a standard chemotherapy regimen with…

A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton*s Tyrosine Kinase (Btk) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

The primary hypothesis of this study is that ibrutinib compared with temsirolimus significantly prolongs PFS in subjects with relapsed or refractory MCL who have received at least 1 prior rituximab-containing chemotherapy regimen.

A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DIFFUSE LARGE B-CELL LYMPHOMA OR CD20+ FOLLICULAR NON-HODGKIN*S LYMPHOMA GRADES 1, 2 OR 3A

To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.

A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (ibritumomab tiuxetan) versus Observation in Patients at Least 60 Years of Age with Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

To evaluate the efficacy and safety of Zevalin compared with observation alone in patients who are in PET-negative complete remission (CR) after first-line R-CHOP or R-CHOP like therapy.

An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 + chlorambucil (GClb), rituximab + chlorambucil (RClb)or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities.

The primary objective of the study is to demonstrate clinically relevant statistical superiority in progression-free survival (PFS) with GClb compared to RClb and Clb alone and RClb compared to Clb [GClb vs Clb; GClb vs RClb; RClb vs Clb] in…

Response to vaccination in lymphoma patients treated with CHOP and rituximab.

To investigate what the ideal moment to vaccinate would be, early (after 2-6 months) or late (after 9-12 months) after cessation of rituximab. Secondly to study the immune-response to vaccination with influenza virus vaccine after treatment with…

Anti-cancer drugs and their effect on the ubiquitin cycle

1. To decipher the biological basis underlying the alterations in ubiquitination of histones in response to anthracyclines and proteasome inhibitors.2. to find out whether the combined use of anthracyclines and proteasome inhibitors has additive or…

A COMPARATIVE, RANDOMIZED, PARALLEL-GROUP, MULTI-CENTRE, PHASE IIIB STUDY TO INVESTIGATE THE EFFICACY OF SUBCUTANEOUS (SC) RITUXIMAB VERSUS INTRAVENOUS (IV) RITUXIMAB BOTH IN COMBINATION WITH CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH CD20 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL).

The objective of this study is to gather more information to find out if one of these rituximab administration methods is more effective and safer in the treatment of DLBCL patients. This study will also collect information on patient satisfaction…

A global randomized multicenter Phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (TRANSFORM)

Primary Objective:To compare the efficacy in subjects treated with JCAR017 versus subjects treated according to standard of care (SOC) defined as event-free survival (EFS) Key Secondary Objectives:To compare additional parameters of efficacy in…

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma.

Run-in Part (Part 1)Objectives Primary* Confirm that the pharmacokinetics in pediatric subjects is consistent with that in adults Secondary* Evaluate the safety and tolerability of ibrutinib in combination with RICE or RVICI background therapy in…

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Primary Objective- To determine if axicabtagene ciloleucel is superior to SOC as measured by event-free survival (EFS), as determined by blinded central reviewSecondary Objectives- To evaluate the effect of axicabtagene ciloleucel compared to SOC on…

Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial

This study has been transitioned to CTIS with ID 2023-508343-48-00 check the CTIS register for the current data. To compare tisagenlecleucel treatment strategy to SOC treatment strategy with respect to delaying the composite event of disease…

HOVON 133 MCL/TRIANGLE: autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma - a randomized European MCL Network trial

This study has been transitioned to CTIS with ID 2024-511235-10-00 check the CTIS register for the current data. To establish one of three study arms, R-CHOP/R-DHAP followed by ASCT (control arm A), R-CHOP + ibrutinib / R-DHAP followed by ASCT and…

A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation

This study has been transitioned to CTIS with ID 2023-506270-13-00 check the CTIS register for the current data. The primary objective is to determine superiority of MB CART2019.1 treatment compared to standard-of-care (SoC) therapy with R GemOx (…

The Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma

This study has been transitioned to CTIS with ID 2023-504805-35-00 check the CTIS register for the current data. Dose Escalation PhasePrimary - Evaluate the safety and tolerability of epcoritamab in combination with other agents Secondary-…

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

This study has been transitioned to CTIS with ID 2023-507695-52-00 check the CTIS register for the current data. To compare progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor…

A phase II non-inferiority study comparing point-of-care produced CAR T-cell to commercial CAR T-cells in patients with relapsed/refractory Non-Hodgkin Lymphoma

This study has been transitioned to CTIS with ID 2024-511979-15-00 check the CTIS register for the current data. Primary objective: • To compare progression free survival (PFS, of patients randomized to investigational point-of-care (PoC) ARI-0001…

A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)

This study has been transitioned to CTIS with ID 2023-503916-33-00 check the CTIS register for the current data. Primary Objective• Evaluate the efficacy of loncastuximab tesirine combined with rituximab compared to standard immunochemotherapy…

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator*s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

This study has been transitioned to CTIS with ID 2023-504830-23-00 check the CTIS register for the current data. Compare the clinical efficacy of Epcoritamab to SOC (R-GemOx or BR)

A Phase 3, Randomized, Open-Label, Multicenter Study
Comparing the Efficacy and Safety of the Bruton*s Tyrosine
Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects
with Waldenström*s Macroglobulinemia (WM)

Primary (Cohort 1)* To compare the efficacy of zanubrutinib (BGB-3111) vs ibrutinib in subjects with MYD88MUT WMSecondary (Cohort 1) * To further compare the efficacy, clinical benefit, and anti-lymphoma effects of BGB-3111 vs ibrutinib in subjects…